Form 4: Acadia Pharmaceuticals PAO Sells Shares

Principal Accounting Officer James Kihara sold 5,401 shares of Acadia Pharmaceuticals common stock on May 26, 2026.

Summary

• James Kihara, Principal Accounting Officer of Acadia Pharmaceuticals, sold 5,401 shares of common stock.
• The shares were sold at a weighted average price of $21.18 per share.
• Following the transaction, Kihara retains beneficial ownership of 24,509 shares.
• The sale was executed on May 26, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale appears to be a routine transaction by an executive rather than a strategic shift.

Positives

• The reporting person maintains a significant remaining stake of 24,509 shares in the company.

Negatives

• Insider selling activity can sometimes be perceived by the market as a lack of confidence in near-term price appreciation.

Risks

• Market volatility affecting the share price of ACAD.

Future Outlook

No specific forward-looking guidance or operational outlook was provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling by accounting officers is common and often related to tax obligations or personal financial planning rather than a reflection of company performance.

Comparison to Industry Standards

• Insider transactions are standard regulatory disclosures for publicly traded biopharmaceutical companies.
• The volume of shares sold represents a small fraction of the total outstanding shares of Acadia Pharmaceuticals.

Stakeholder Impact

• Minimal impact expected on shareholders as the transaction size is relatively small.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

ACAD, Acadia Pharmaceuticals, Insider Trading, Form 4, Equity Sale